The Evening Runway with Hongbin Jeong, Roshan Gidwani & Chua Tian Tian (4pm - 7pm)Under the Radar: The role of Generative AI on drug discovery – Insilico Medicine’s CEO on positioning against large pharma players; Global market for AI enabled drug discovery to grow at a CAGR of 26.3%; Collaboration with Sanofi worth up to US$1.2b
From content writing, to providing human-like responses in chatbots, and to even coding. Generative AI has made its potential known to the world with the introduction of ChatGPT.
But besides, did you know that generative AI can be used in the process of drug discovery as well?
Today we speak with Insilico Medicine, a clinical stage AI driven drug discovery company that is delivering breakthrough solutions to discover and develop medicines in areas such as cancer, immunity and ageing.
The company was selected by NVIDIA as one of the top 5 AI companies for its potential for social impact back in 2017. But how does it work, and what does a new drug discovery mean for the company?
Separately, Insilico Medicine had also signed a strategic research collaboration with pharmaceutical giant Sanofi in a deal worth up to US$1.2 billion last November. So, what is the status right now?
On Under the Radar, Drive Time’s finance presenter Chua Tian Tian posed these questions to Dr Alex Zhavoronkov, CEO of Insilico Medicine.
